Your shopping cart is currently empty

BAY-850 is a selective and potent inhibitor of adenosine triphosphatase family protein 2 (ATAD2) (IC50: 166 nM) that inhibits ovarian cancer growth and metastasis in in vitro and in vivo models.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $44 | - | In Stock |
| Description | BAY-850 is a selective and potent inhibitor of adenosine triphosphatase family protein 2 (ATAD2) (IC50: 166 nM) that inhibits ovarian cancer growth and metastasis in in vitro and in vivo models. |
| Targets&IC50 | ATAD2:166 nM, tetra-acetylated peptide:157 nM, tetra-acetylated peptide:115 nM (Kd) |
| In vitro | In a TR-FRET assay, BAY-850 competes with the binding of a mono-acetylated Histone H4 N-terminal peptide to ATAD2 BD, showing an IC50 of 166 nM. BAY-850 displaces the tetra-acetylated peptide with an IC50 of 157 nM and a KD of 115 nM, respectively. The unprecedented isoform selectivity of BAY-850 suggests a mode of action different from those exhibited by canonical BD inhibitors[1]. |
| Molecular Weight | 654.24 |
| Formula | C38H44ClN5O3 |
| Cas No. | 2099142-76-2 |
| Smiles | COc1cc(Cl)c(cc1-c1ccc(CN[C@H](C)c2ccc(C)cc2)o1)C(=O)N[C@@H](CN[C@@H]1CC[C@H](N)CC1)Cc1ccc(cc1)C#N |
| Relative Density. | 1.24 g/cm3 (Predicted) |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||
| Solubility Information | H2O: <0.1 mg/mL (Insoluble) DMSO: 50 mg/mL (76.42 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 5 mg/mL (7.64 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
| |||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.